Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITACA-S: Sequential Chemo vs 5-FU/LV in Gastric Cancer
NCT01640782Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2005
- Primary completion
- Jan 2013
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, docetaxel and Cisplatin micelle injection (HA132) in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Progression Free Survival at 3 years. Started Feb 2005; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabdocetaxelCisplatin micelle injection (HA132)
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01640782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640782.